Molecular Characteristics of Choledochal Cysts in Children: Transcriptome Sequencing

Yong Lv\textsuperscript{1*}, Xiaolong Xie\textsuperscript{1*}, Lihui Pu\textsuperscript{2}, Qi Wang\textsuperscript{1}, Jiayin Yang\textsuperscript{3}, Siyu Pu\textsuperscript{1}, Chengbo Ai\textsuperscript{1}, Yi Liu\textsuperscript{4}, Jing Chen\textsuperscript{1*} and Bo Xiang\textsuperscript{1*}

\textsuperscript{1}Laboratory of Pediatric Surgery, Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, China, \textsuperscript{2}Department of Critical Care, West China Hospital, Sichuan University, Chengdu, China, \textsuperscript{3}Liver Transplant Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China, \textsuperscript{4}Department of Rheumatology and Immunology, Rare Diseases Center, Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

A choledochal cyst (CC) is a common congenital biliary disease in children, yet the underlying molecular bases for the cystic and fusiform clinical subtypes are unknown. RNA sequencing (RNA-seq) has been performed on 22 high-quality CC samples, including 12 cystic CC and 10 fusiform CC samples, to search for molecular features. Weighted gene co-expression network analysis (WGCNA) was performed to identify key modules associated with clinical subtypes. Bioinformatic analyses were conducted to elucidate potential mechanisms. Then, we constructed protein–protein interaction (PPI) networks to identify candidate hub genes related to CC. Finally, we used the support vector machine (SVM) to eliminate redundant features and screen out the hub genes. The selected gene expression was determined in CC patients through quantitative real-time polymerase chain reaction (PCR). A total of 6,463 genes were found to be aberrantly expressed between cystic CC and fusiform CC. Twelve co-expression modules that correlated with clinical subtypes of CC were identified and assigned representative colors. Among the 12 modules, the blue module was considered the key module. Two functionally distinct sets of dysregulated genes have been identified in two major subtypes, metabolism-related genes in cystic CC and immune-related genes in fusiform CC. A total of 20 candidate hub genes that were correlated with clinical subtypes were found in the blue module. In addition, we found ERBB2 and WNT11 that have not been studied in CC and verified their differential expression in CC through quantitative real-time PCR experiments. For the first time, we have described the transcriptome characteristics of CC. These results suggest that cystic CC and fusiform CC have different molecular mechanisms. The bi-omics-identified novel candidate genes and pathways might be helpful for personalized treatment and are of great clinical significance for CC.

Keywords: transcriptome, choledochal cysts, weighted gene co-expression network analysis, children, bioinformatics
INTRODUCTION

A choledochal cyst (CC), also known as congenital biliary dilatation (CBD), is a common congenital biliary disease in children characterized by dilatation of extrahepatic biliary tract. The incidence of CCs in Asians is significantly higher than that in Europeans and Americans, and the incidence in Asian populations can be as high as 1/1,000 (van den Eijnden et al., 2017). CCs mostly occur in infant and children, particularly in females, and the incidence ratio of male to female is about 1:4 (Atkinson and Davenport, 2014). The etiology of CC is unknown, which may be related to an anomalous pancreaticobiliary junction, bile duct dysplasia, and other factors (Friedmacher et al., 2019). However, these theories cannot explain the pathogenesis of all types of CCs. There are obvious differences in epidemiology, imaging, and clinical features among different types of CCs. CCs were divided into five types in 1977 by Todani et al. (1977). The classification was complicated and inaccurate. Todani's type II and type III pathologies were rare in children, and type V was Caroli disease that requires a different management. It fails to provide a surgical guideline specific to the subtypes (Makin and Davenport, 2012). The main subtypes of CCs are cystic CCs (Ia) and fusiform CCs (Ic). At present, dividing CCs into two types (cystic and fusiform extrahepatic dilatation) is the most widespread classification method, which has great advantages in clinical diagnosis and treatment (Diao et al., 2011).

The two principal extrahepatic phenotypes, cystic (Ia) and fusiform (Ic) extrahepatic dilatation, making up more than 95% of CCs, have clear clinical and physiological differences. Different subtypes require different operative strategies (Jung et al., 2012). These types of CCs were closely related to malignant transformation (Soares et al., 2014). However, the molecular processes associated with CCs remain largely unknown, and there are insufficient molecular criteria to distinguish clinical subtypes. Some CC cases occur in families, suggesting that genetic predisposition plays a role in its pathogenesis (Clifton et al., 2006). Patients with cystic biliary dilatation have more severe hepatic dysfunction, and the ages were younger than those with fusiform biliary dilatation. We do not know, however, whether cystic biliary dilatation and fusiform biliary dilatation have a distinct pathogenesis at the molecular level. No microarray studies and RNA sequencing (RNA-seq) were used to identify distinct molecular processes for CCs. So far, further basic science and research into the etiology of CCs were absent, whether the molecular pathways are different in clinical subtypes of this complex disorder. In addition, if the transcriptomes of homogeneous samples between the cystic and nodular subtypes are compared, a more complete set of dysregulated genes in each subtype may be found.

Weighted gene co-expression network analysis (WGCNA) is a systems biology approach to describe gene association patterns between different samples (Liu et al., 2021). According to the association between gene sets and phenotypes, it can be used to identify highly collaborative gene sets and to identify candidate biomarker genes or therapeutic targets (Panahi and Hejazi, 2021). Machine learning is one of the important branches of artificial intelligence science, which can mine new data features and results from massive data. With the development of high-throughput sequencing technology, more genomics data need to be processed, and the application of machine learning can solve this problem (Panahi et al., 2019). The broad goal of this study was to systematically explore CC molecular signatures associated with clinical subtypes. We carried out transcriptome sequencing on high-quality CC samples. Furthermore, we used the WGCNA to find highly correlated gene modules with clinical traits and to identify the key genes in selected modules. The discovery of novel candidate CC-related gene is important for subsequent functional and mechanistic studies of CCs.

MATERIALS AND METHODS

Study Participants

The study was approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee, and informed consent was obtained from all participants. Twenty-two patients with CCs (12 cystic and 10 fusiform extrahepatic dilatation) were consecutively recruited between January and December 2020 from the Pediatric Surgery Department of West China Hospital, Sichuan University. All children underwent a collection of medical history and had hepatobiliary ultrasonography and magnetic resonance cholangiopancreatography. All children underwent cyst excision and Roux-Y hepaticojejunostomy. The CC samples were collected from all participants and stored in liquid nitrogen. Transcriptomics analysis was performed by Novogene Co., Ltd. (Beijing, China). The raw data in this article have been deposited in National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus and are accessible through GEO Series accession number GSE179075.

Differentially Expressed Gene Screening

Differentially expressed genes (DEGs) between cystic and fusiform CCs were screened from the RNA-seq data with the “edgeR” package. Significantly changed genes were selected with p-value < 0.05 and log₂ fold change| ≥ 1.

Construction of Weighted Gene Co-expression Network

The co-expression network of the DEGs was constructed by the R package “WGCNA” (Langfelder and Horvath, 2008). The network construction procedure included the following main steps: (1) select the appropriate soft threshold (weighting coefficient) and define the similarity matrix; (2) the similarity matrix was then converted into an adjacency matrix by using a power adjacency function; (3) transform the adjacency matrix into a topological overlap matrix (TOM); (4) the hierarchical clustering was used to produce hierarchical cluster tree from TOM-based dissimilarity (dissTOM); and (5) modules were

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179075
defined as branches of the hierarchical cluster tree using the dynamic tree cut method.

Identification of Clinically Significant Modules

The main purpose of WGCNA is to link key genes in the co-expression network with external clinical trials. The association between the gene modules and clinical characteristic was analyzed as follows: (1) calculate the module eigengene (ME) of each module, and ME represents the overall expression level of the module. (2) Identify module membership (MM), and MM represented the correlation of gene expression profile with the ME. The larger the absolute value of MM, the more important the gene is in the module. (3) Extract gene significance (GS) and module significance (MS). MS is the average absolute GS measure for all genes in a given module. The higher the absolute value of GS, the more biologically significant is the gene (Langfelder and Horvath, 2008).

Functional Enrichment Analysis

To obtain further insights into the function of the DEGs in the module most related to CCs, we referred to the Metascape2 to perform the enrichment analysis (Zhou et al., 2019). \( p < 0.05 \) was set as the cutoff. The R software was adopted to show the results graphically. Gene set enrichment analysis (GSEA) was performed to identify the enriched pathways based on the expression profiles between the cystic and fusiform CC subtypes. The R package “clusterprofiler” was used to conduct GSEA. The h.all.v7.2.symbols.gmt in Molecular Signatures Database (MSigDB) was selected as the reference gene set, and adjusted \( p \)-value < 0.05 was chosen as the cutoff criteria.

Featured Gene Selection and the Support Vector Machine Classifier Construction

The genes selected from the WGCNA were uploaded to the STRING3 database, and the protein–protein interactions (PPIs) between these genes were obtained by online tools, and the network was mapped. Cluster analysis extracts tightly connected regions of biological networks and isolates modules of importance in the network. Based on the constructed PPIs, the MCODE plug-in was used to find key modules (Bandettini et al., 2012). Subsequently, selecting nodes with MCODE score \( \geq 2 \), degree cutoff = 2, node score cutoff = 0.2, max depth = 100, and \( k-\)score = 2 and clustering analysis result in the candidate hub genes. The featured selection technique is an efficient tool for identifying meaningful information from a given gene dataset; support vector machine recursive feature elimination (SVM-RFE) is a popular feature selection technique and has exhibited promising and expanding applications for the analysis of high-dimensional data (Xu et al., 2021). We applied the machine learning method to filter candidate hub genes. The fivefold cross-validation method was used to split the data and assign random numbers. When halve above was set to 100, the order of feature vector was obtained.

RNA Isolation and Quantitative Reverse Transcription-PCR

Another 24 CC tissues (12 cystic and 12 fusiform) were used for RNA isolation. Total RNA was isolated from CC tissue with TRIzol. To assess gene expression, 1 \( \mu \)g RNA was used for cDNA synthesis with NovoScript\textsuperscript{®} 1st Strand cDNA Synthesis SuperMix (Novoprotein Scientific Inc., China). PCR amplification was performed at 95\(^\circ\)C for 5 min, followed by 48 cycles at 95\(^\circ\)C for 10 s, 60\(^\circ\)C for 10 s, and 72\(^\circ\)C for 20 s in a real-time PCR system with SYBR green (Applied Biosystems). For each sample, we used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as inner reference to normalize target gene expression. Primers for quantitative reverse transcription-PCR (qRT-PCR) were designed with Primer-BLAST in the NCBI. Primers are listed as follows. Relative changes in gene expression were determined using the \( 2^{-\Delta \Delta C_{\text{t}}} \) method (Schmittgen and Livak, 2008).

|     | Fusiform (Ic) | Cystic (Ia) | \( p \)-value |
|-----|--------------|------------|--------------|
| Total | 10           | 12         | 0.095        |
| Female | 5            | 10         | 83.30%       |
| Male | 5            | 2          | 16.70%       |
| Age (months) | 35 (30–42) | 27 (15–34) | 0.069        |
| DB (\( \mu \)mol/L) | 12.9 (2.4–63.7) | 3.8 (1.3–12.1) | 0.093        |
| TB (\( \mu \)mol/L) | 19.9 (9.4–69.7) | 9.1 (6.1–19.1) | 0.140        |
| IB (\( \mu \)mol/L) | 5.9 (4.8–9.1) | 4.8 (3.5–6.5) | 0.180        |
| ALT (U/L) | 65 (15–189) | 27 (16–113) | 0.628        |
| AST (U/L) | 54 (36–90) | 59 (33–118) | 0.872        |
| G-GT (U/L) | 374 (84–777) | 82 (40–484) | 0.314        |
| ALP (U/L) | 416 (318–553) | 284 (235–386) | 0.140        |
| AMY (U/L) | 68 (50–71) | 66 (52–168) | 0.674        |
| PT (s) | 11.3 (10.6–11.9) | 11 (10.8–11.1) | 0.497        |
| APTT (s) | 29.3 (28.7–29.9) | 28.7 (26.5–30.7) | 0.418        |

The parameters are presented as the median (IQR), IQR, interquartile range; DB, direct bilirubin; TB, total bilirubin; IB, indirect bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; G-GT, \( \gamma \)-glutamyl transpeptidase; ALP, alkaline phosphatase; AMY, amylose; PT, prothrombin time; APTT, activated partial thromboplastin time.
FIGURE 1 | The volcano plot and enrichment analysis of differentially expressed genes (DEGs). (A) Volcano plot of DEGs. Red, upregulated genes in cystic choledochal cysts (CCs); blue, downregulated genes in cystic CCs. (B) The enriched Gene Ontology (GO) terms of upregulated DEGs. (C) The enriched GO terms of downregulated DEGs. (D) The enriched pathways of upregulated DEGs. (E) The enriched pathways of downregulated DEGs.
identified between the two subtypes and selected for subsequent analysis. Among the DEGs, 2,750 genes were upregulated and 3,731 genes were downregulated in cystic CCs (Figure 1A).

**Molecular Pathways Involved in Cystic and Fusiform CCs**

Functional enrichment on these DEGs was performed to identify possible biological functions. The upregulated DEGs in cystic CCs were obviously enriched in biological processes (BPs) such as epithelial cell differentiation and regulation of hormone levels (Figure 1B). For molecular function (MF), the upregulated DEGs were enriched in oxidoreductase activity, lipid binding, and so on (Figure 1B). For cell component (CC), the upregulated DEGs were distinctly enriched in the apical part of the cell, apical plasma membrane, and so on (Figure 1B). For BP, the downregulated DEGs in cystic CCs were obviously enriched in lymphocyte activation, regulation of cell adhesion, and so on (Figure 1C). For MF, the downregulated DEGs were enriched in calcium ion binding, receptor regulator activity, and so on (Figure 1C). For CC, the downregulated DEGs were distinctly enriched in the extracellular matrix, collagen-containing extracellular matrix, and so on (Figure 1C). The screened DEGs were analyzed by the pathway analysis for a more in-depth understanding. The upregulated DEGs were enriched in the tight junction, phosphatidylinositol-3-phosphate/akt (PI3K/AKT)-signaling pathway, protein digestion and absorption signaling pathways, and so on (Figure 1D), while the downregulated DEGs were enriched in cytokine–cytokine receptor interaction, mitogen-activated protein kinase (MAPK) signaling pathway, Ras signaling pathway, and so on (Figure 1E).

**Gene Set Enrichment Analysis Result Between Cystic and Fusiform CCs**

The large differences between DEGs observed in cystic and fusiform CCs suggest that these two major subtypes are due to different molecular mechanisms. In order to investigate the relevant MFs and pathways of the DEGs between these two major subtypes, we used GSEA software to compare the pathways between cystic and fusiform CCs. The cystic CC group showed many enriched pathways related to endocrine metabolism and hormone regulation compared with the fusiform CC group (Figure 2A). In contrast, the pathways enriched in the fusiform CC group mainly included those associated with immune response and cell morphology (Figure 2B). These results suggest that cystic and fusiform CCs might be two completely different diseases.

**The Weighted Gene Co-expression Modules of CCs**

Connectivity between genes in the network formed the scale-free network distribution when 0.8 was set as the correlation coefficient threshold, the soft-thresholding power was selected as 14 (Figure 3A). Through WGCNA, total 12 co-expression modules were constructed (Figure 3B). The module comprising most genes was the turquoise one, followed by the blue module. The genes that could not be included in any of the modules were put into the gray module, which was reserved for genes identified as not co-expressed. Moreover, these modules were independent of other modules (Figure 3C). The adjacency heatmap of eigengene showed that modules were divided into two clusters (Figure 3D). One cluster included four modules (turquoise, blue, black, and green–yellow modules), while the other included seven modules (brown, magenta, pink, purple, yellow, green, and red modules). We found that the three pairs of modules had higher adjacencies, and they were the black and green–yellow, magenta and pink, and green and red modules, respectively.

**Gene Co-expression Modules Correlated With Clinicopathological Traits**

To determine the clinical significance of the modules, we analyzed the correlation between the above modules and clinical parameters. Module–trait correlation analyses showed that multiple modules were related to CCs (Figure 4A). Each module might represent specific clinical traits of CC patients, and highly co-expressed genes in the same module have potential biological significance. The blue module was significantly positively associated with fusiform CCs ($R = 0.91$, $p = 2e^{-7}$), which indicated that the blue modules were most significantly associated with the CC subtype. Therefore, the blue module was treated as CC subtype-related module in subsequent analyses. To ensure the reliability of the results, we performed correlation analysis between GS for CC subtype and MM for genes in each module to test whether MM values were closely correlated with CC subtypes. The results showed that the correlation coefficient between GS for CC subtype and MM was highest in the blue module (Figure 4B); that is, the blue module was the most positively correlated with CC subtype, which was consistent with the above findings.

**Functional Enrichment Analysis Results of Interesting Gene Sets**

In order to understand the possible biological function of the modules related to histopathological subtypes, enrichment analysis was performed for the genes in each module. The genes in the blue module were mainly enriched in synapse organization, aryline N-acetyltransferase activity, external side of plasma membrane, and so on (Figure 5A). These results suggest that these genes are closely related to cellular component organization or biogenesis. The functional enrichment analysis in other modules showed similar results (Figures 5B–J).

**Protein–Protein Interaction Network of Selected Modules**

To further understand the intrinsic linkage of genes in the blue module, we built a PPI network using the STRING database. Based on the criteria that MM > 0.80 and GS > 0.20, a total of 145 DEGs with high connectivity in blue modules were screened as candidate hub genes. Due to the large node network, we mined the submodules using MCODE software in order to more accurately find the genes affecting the subtype of CCs. A total of 20 nodes and 61 edges were obtained (Figure 6A). Enrichment analysis displayed that the genes in the three modules were chiefly concerned with convergent extension involved in axis elongation, C-C chemokine receptor activity, lateral plasma
membrane, and Wnt signaling pathway (Table 2). As shown in heatmap (Figure 6B), the 20 candidate hub genes could discriminate between the patients with cystic CCs and the patients with fusiform CCs.

**Hub Gene Verification**

We then applied the SVM-RFE algorithm to filter the 20 candidate hub genes in order to identify the optimal feature in CC subtype. Finally, ERBB2 and WNT11 (maximal accuracy = 0.87) were identified as the optimal feature genes to construct the classification model using an SVM (Figure 6C). The qRT-PCR experiments on 12 cystic CCs and 12 fusiform CCs demonstrated that the mRNA expression of ERBB2 was significantly lower in cystic CC samples than that in fusiform CC samples ($t = 3.425$, $p = 0.004$), whereas the mRNA expression of WNT11 was significantly higher in cystic CC samples than that in fusiform CC samples ($t = -3.917$, $p = 0.002$) (Figure 6D).

**DISCUSSION**

The main characteristic of CC is cystic or fusiform dilatation of extrahepatic bile duct. Treatment of CCs depends upon the type of cyst (Pastor et al., 2021). The clinical characteristics of CCs can be measured; the underlying molecular mechanisms for the
clinical subtypes are unknown. Therefore, to better understand and treat CCs, it is pivotal to comprehensively investigate their molecular mechanisms. In this study, we used the DEGs from CC RNA-seq to construct weighted gene co-expression network. Key gene modules associated with the subtype of CC were identified, and the candidate hub genes in modules were detected and their related biological functions and pathways were analyzed. These results have enlightened our knowledge about CCs and might provide some potential molecular therapeutic targets.

We identified 6,463 DEGs between cystic CCs and fusiform CCs. The DEGs were mainly involved in BPs associated with epithelial cell differentiation, regulation of hormone levels, and extracellular matrix. These results indicated that BPs and pathways differed significantly between cystic CCs and fusiform CCs. In addition, GSEA showed that the pathways enriched in cystic CCs are all related to metabolism and hormone regulation, indicating that abnormal bile duct cells might allow them to maintain pathological growth by providing anabolic intermediates for biosynthesis. GSEA indicated that various immune inflammatory responses were strengthened in fusiform CCs compared to cystic CCs, which is consistent with the actual clinical situation. Patients with fusiform CCs usually have severe symptoms such as cholangitis and pancreatitis (Diao et al., 2011). Overall, our enrichment analysis results indicate that BPs and pathways related to inflammatory and metabolism have a critical impact on CCs.

Weighted gene co-expression network analysis can detect clusters of highly correlated genes and presents many unique advantages over other methods and has been widely used in biomedical research (Hu and Bi, 2020). We identified 12 modules and found strong correlations of blue module with CC subtypes. The result suggested that genes within the blue modules may serve as potential markers between cystic and fusiform CCs. To identify key candidate genes in the blue modules, a PPI network was constructed, and genes were filtered with MCODE plug-in. We found that the genes were enriched in Wnt signaling pathway. The key signaling pathways are closely related to the basic developmental processes and the control of asymmetric cell division (Zong et al., 2021). A previous study found that the Wnt pathway...
was activated in congenital CCs, but the activation level was lower than that in cholangiocarcinoma (Chen et al., 2016). Because CCs belong to a group of diseases characterized by chronic epithelial inflammation and recurrent cholangitis, a carcinoma can occur anywhere along the bile duct. We need to further elucidate the role of the Wnt pathway in CCs. There may be a Wnt inhibitor that prevents malignant transformation in CCs.
We then applied the SVM-RFE algorithm to filter the 20 candidate hub genes in the blue module to identify the optimal feature in CC subtypes. We found that ERBB2 and WNT11 were the optimal feature genes to distinguish cystic and fusiform CCs. The qRT-PCR experiments showed that the mRNA expression of ERBB2 was significantly lower in cystic CCs, whereas the mRNA expression of WNT11 was significantly higher in cystic CCs. ERBB2, also known as HER2, encodes a member of the epidermal growth factor receptor family of receptor tyrosine kinases. The protein encoded by ERBB2 is detected in the surface epithelium in large and septal bile ducts and are not detected in peripheral small ducts (Chow et al., 1995). High expression and activation of ERBB2 have been found in biliary lithiasis and primary sclerosing cholangitis and have been implicated in pathologic proliferation of cholangiocytes (Pellat et al., 2018). Immunohistochemistry of adult biliary cysts revealed variable expression of ERBB2 in cyst epithelia and suggested that cyst formation happens in a non-proliferative way (Waanders et al., 2008). The anti-ERBB2 therapy, pertuzumab, inhibited the in vivo growth of subcutaneous tumors in xenografted models (Kawamoto et al., 2015). Many risk factors for cholangiocarcinoma are associated with chronic inflammatory diseases, and the immune system plays a crucial role in the etiology of cholangiocarcinoma. Uncovering the molecular mechanisms of inflammatory response in chronic bile duct disease and the pathways leading to neoplastic transformation of bile duct epithelial cells is a crucial step in developing new strategies to prevent tumor development. In cholangiocarcinoma, ERBB2 is a key mediator of bile duct disease.
**FIGURE 6** | Identification of hub genes. (A) The protein–protein interaction (PPI) network. (B) Heatmap of the 20 genes. (C) Support vector machine recursive feature elimination (SVM-RFE) algorithm to screen hub genes. (D) The violin plots of genes between cystic and fusiform CCs.

**TABLE 2** | The enrichment analysis of candidate hub genes.

| Term ID | Term description | Count | False discovery rate | Matching proteins in network |
|---------|------------------|-------|----------------------|-----------------------------|
| hsa04310 | Wnt signaling pathway | 6 | 5.29E–07 | SFRP5, WNT9A, SFRP2, WIF1, WNT11, FZD3 |
| hsa04060 | Cytokine–cytokine receptor interaction | 4 | 0.0012 | ACKR3, CCR10, IL6, CCR3 |
| hsa04151 | PI3K–Akt signaling pathway | 4 | 0.0025 | ERBB3, ERBB2, IL6, BDNF |
| GO:0060028 | Convergent extension involved in axis elongation | 2 | 0.0004 | SFRP2, WNT11 |
| GO:0048570 | Notochord morphogenesis | 2 | 0.00074 | GLI1, WNT11 |
| GO:1900122 | Positive regulation of receptor binding | 2 | 0.00087 | MMP9, BDNF |
| GO:0004888 | Transmembrane signaling receptor activity | 10 | 4.75E–06 | SFRP5, ERBB3, ERBB2, ACKR3, SFRP2, GPR37, CCR10, FZD3, CCR3, S1PR2 |
| GO:0017147 | Wnt-protein binding | 4 | 4.75E–06 | SFRP5, SFRP2, WIF1, FZD3 |
| GO:0038023 | Signaling receptor activity | 11 | 4.75E–06 | SFRP5, ERBB3, ERBB2, ACKR3, SFRP2, GPR37, CCR10, AR, FZD3, CCR3, S1PR2 |
| GO:0005576 | Extracellular region | 11 | 0.00085 | SFRP5, ERBB3, WNT9A, SFRP2, WIF1, PNOC, WNT11, MMP9, DKK3, IL6, BDNF |
| GO:0005615 | Extracellular space | 8 | 0.00085 | SFRP5, ERBB3, WNT9A, SFRP2, WNT11, MMP9, DKK3, IL6 |
| GO:0043235 | Receptor complex | 4 | 0.0081 | ERBB3, ERBB2, GPR37, IL6 |

SFRP5, secreted frizzled-related protein 5; WNT9A, protein Wnt-9a; SFRP2, secreted frizzled-related protein 2; WIF1, Wnt inhibitory factor 1; WNT11, protein Wnt-11; FZD3, frizzled-3; ACKR3, atypical chemokine receptor 3; CCR10, C-C chemokine receptor type 10; IL6, interleukin-6; CCR3, C-C chemokine receptor type 3; ERBB3, receptor tyrosine-protein kinase erbB-3; ERBB2, receptor tyrosine-protein kinase erbB-2; BDNF, brain-derived neurotrophic factor; GLI1, zinc finger protein GLI1; MMP9, matrix metalloproteinase-9; GPR37, prosaposin receptor GPR37; S1PR2, sphingosine 1-phosphate receptor 2; AR, androgen receptor; PNOC, prepronociceptin; DKK3, dickkopf-related protein 3.
carcinogenesis, and ERBB2 overexpression and hyperactivation are present throughout tumorigenesis (Jacobi et al., 2021). In our study, ERBB2 expression was found to be increased in the fusiform CCs. We hypothesized that overexpression of ERBB2 may be a risk factor for malignant transformation of fusiform CCs. Evaluation of anti-HER2 agents in fusiform CCs may produce clinical implications. The protein encoded by WNT11 has been implicated in several developmental processes, including regulation of cell fate and patterning during embryogenesis (Monga, 2015). WNT11 is notably upregulated in a liver injury model, and it may be arising from macrophages (Jiang et al., 2019). Clinical and preclinical studies have shown that activation of the Wnt signaling pathway plays a key role in the induction and progression of cholangiocarcinoma (Zhang et al., 2020). In bile duct-ligated mice, adenovirus carrying Dickkopf-1 (WNT antagonist) was able to significantly reduce cholangiocyte proliferation. In addition, WNT antagonists stimulated the secretion of pro-inflammatory mediators by cystic epithelial cells (Cannito et al., 2018). In our study, WNT11 was found to be overexpressed in cystic CCs, suggesting that WNT11 may be associated with abnormal cholangiocyte proliferation. Our results indicate that ERBB2 and WNT11 may play critical roles in CCs. If the results from further studies support our findings, ERBB2 and WNT11 may be promising diagnostic or therapeutic markers for CCs.

This study has some limitations. First, further experiments will elucidate the molecular mechanism of these candidate hub genes on CCs are needed. Second, like any analysis method, reliable results depend essentially on more high-quality samples. The sample size is relatively small. Therefore, further studies that include more clinical samples will be needed to confirm our findings and to more accurately clarify the possible mechanisms.

Overall, we used WGCNA to identify gene co-expression modules associated with CCs and revealed the candidate hub genes and potential molecular mechanisms related to CC subtypes. As far as we know, this is the first study to investigate the gene expression profile characteristics of patients with CCs. In addition, we identified candidate hub genes and BPs and pathways. These results might be helpful for personalized treatment and are of great clinical significance for CCs.

DATA AVAILABILITY STATEMENT

The RNA-seq raw data in this article have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE179075 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE179075).

REFERENCES

Atkinson, J. J., and Davenport, M. (2014). Controversies in choledochal malformation. South Afr. Med. J. 104, 816–819. doi: 10.7196/samj.8633
Bandettini, W. P., Kelman, P., Mancini, C., Booker, O. J., Vasu, S., Leung, S. W., et al. (2012). MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J. Cardiovasc. Magn. Reson. 14:83. doi: 10.1186/1532-429x-14-83
Cannito, S., Milani, C., Cappon, A., Parola, M., Strazzabosco, M., and Cadamuro, M. (2018). Fibroinflammatory liver injuries as preneoplastic condition in cholangiopathies. Int. J. Mol. Sci. 4:19. doi: 10.3390/ijms19123875

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

BX: study concept, and management and coordination responsibility for the research activity planning. JC: study concept, experiment design, data analysis, and critical revision of the manuscript for important intellectual concept. JY: sample acquisition, analysis and interpretation of data for the work, drafting the work and revising it critically for important intellectual content. YLv: study concept, data analysis and drafting of the manuscript, and implementation of the computer code and supporting algorithms. XX: sample collection, conducting a research and investigation process, data analysis, and drafting of the manuscript. LP: performing the experiments and data collection. QW: sample collection, scrub data, and maintain research data. SP and CA: sample and data collection. YLi: critical advice on study design and found support for this project. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported by the Scientific Research Starting Foundation for Introduced Talents (JC), Major Project of Sichuan Science and Technology Department (2020YFS0108), and 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Project Nos. ZYJC18003 and 2021HXFH020).

ACKNOWLEDGMENTS

We would like to thank Professor Xianming Mo, Ph.D., Ran Lu, and other members of the Laboratory of Stem Cell Biology, West China Hospital, Sichuan University, for their generous help in methodology and reagents. We are also grateful for the technical support of Yaohui Li and Yunjing Wan from the Laboratory of Pediatric Surgery, West China Hospital, Sichuan University.
Chen, W., Liang, J., Huang, L., Cai, J., Lei, Y., Lai, J., et al. (2016). Characterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approach. *Eur. J. Histochem.* 60:2536. doi: 10.2014/ejh.2016.2536

Chow, N. H., Huang, S. M., Chan, S. H., Mo, L. R., Hwang, M. H., and Su, W. C. (1993). Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. *Anticancer Res.* 13, 1055–1059.

Clifton, M. S., Goldstein, R. B., Slavotinek, A., Norton, M. E., Lee, H., Farrell, J., et al. (2006). Prenatal diagnosis of familial type I choledochal cyst. *Pediatrics* 117, e396–e600. doi: 10.1542/peds.2005-1411

Diao, M., Li, L., and Cheng, W. (2011). Congenital biliary dilatation may consist of 2 disease entities. *J. Pediatr. Surg.* 46, 1503–1509. doi: 10.1016/j.jpedsurg.2010.12.022

Friedmacher, F., Ford, K. E., and Davenport, M. (2019). Choledochal malformations: global research, scientific advances and key controversies. *Pediatric Surg. Int.* 35, 273–282. doi: 10.1007/s00383-018-4392-4

Hu, V. W., and Bi, C. (2020). Phenotypic subtyping and re-analyses of existing transcriptomic data from autitic probands in simplex families reveal differentially expressed and ASD trait-associated genes. *Front. Neurol.* 11:578972. doi: 10.3389/fneur.2020.578972

Jacobi, O., Ross, J. S., Goshen-Lago, T., Haddad, R., Moore, A., Sulkes, A., et al. (2021). ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway. *Oncol. Res. Treat.* 44, 20–27. doi: 10.11193/00051919

Jiang, A., Okabe, H., Popovic, B., Prezioso, M. E., Pradhan-Sundd, T., Poddar, M., et al. (2019). Loss of Wnt secretion by macrophages promotes hepatobiliary injury after administration of 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine Diet. *Am. J. Pathol.* 189, 590–603. doi: 10.1016/j.ajpath.2018.11.010

Jung, K., Han, H. S., Cho, J. Y., Yoon, Y. S., and Hwang, D. W. (2012). Is preoperative subclassification of type I choledochal cyst necessary? *Korean J. Radiol.* 13(Suppl. 1), S112–S116. doi: 10.3348/kjr.2012.13.S1.S112

Kawamoto, T., Ishige, K., Thomas, M., Yamashita-Kashima, Y., Shu, S., Ishikura, N., et al. (2015). Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. *J. Gastroenterol.* 50, 467–479. doi: 10.1007/s00268-016-4061-9

Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation network analysis. *BMC Bioinform.* 9:559. doi: 10.1186/1471-2105-9-559

Liu, S., Zeng, F., Fan, G., and Dong, Q. (2021). Identification of hub genes and construction of a transcriptional regulatory network associated with tumor recurrence in colorectal cancer by weighted gene co-expression network analysis. *Front. Genet.* 12:649752. doi: 10.3389/fgene.2021.649752

Makin, E., and Davenport, M. (2012). Understanding choledochal malformation. *Arch. Dis. Childh.* 97, 69–72. doi: 10.1136/adc.2010.195974

Monga, S. P. (2015). β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. *Gastroenterology* 148, 1294–1310. doi: 10.1053/j.gastro.2015.02.056

Panahi, B., Frahadian, M., Dums, J. T., and Hejazi, M. A. (2019). Integration of cross species RNA-seq meta-analysis and machine-learning models identifies the most important salt stress-responsive pathways in microalg Dunaliella. *Front. Genet.* 10:752. doi: 10.3389/fgene.2019.00752

Panahi, B., and Hejazi, M. A. (2021). Weighted gene co-expression network analysis of the salt-responsive transcriptomes reveals novel hub genes in green halophytic microalgae Dunaliella salina. *Sci. Rep.* 11:1607. doi: 10.1038/s41598-020-80943-3

Pastor, P., Ocaña, J., González, A., Nuñez, J., García, A., Garcia, J. C., et al. (2021). Choledochal cysts surgical management: retrospective and historical comparative analysis. *Cirugía Española.* S0009-739X(20)30318-3. doi: 10.1016/j.ciresp.2020.10.003

Pellat, A., Vaquero, J., and Fouassier, L. (2018). Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. *Hepatology (Baltimore, Md).* 67, 762–773. doi: 10.1002/hep.29350

Schmittgen, T. D., and Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 3, 1101–1108. doi: 10.1038/nprot.2008.73

Soares, K. C., Arnaoutakis, D. J., Kamel, I., Rastegar, N., Anders, R., Matthei, S., et al. (2014). Choledochal cysts: presentation, clinical differentiation, and management. *J. Am. Coll. Surg.* 219, 1167–1180. doi: 10.1016/j.jamcollsurg.2014.04.023

Todani, T., Watanabe, Y., Naruse, M., Tabuchi, K., and Okajima, K. (1977). Congenital bile duct cysts: classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. *Am. J. Surg.* 134, 263–269. doi: 10.1016/0002-9610(77)90359-2

van den Eijnden, M. H. A., de Kleine, R. H. J., de Blauwe, I., Peeters, P., Koot, B. P. G., Oomen, M. W. N., et al. (2017). Choledochal malformation in children: lessons learned from a Dutch national study. *World J. Surg.* 41, 2631–2637. doi: 10.1007/s00268-017-4064-x

Waanders, E., Van Krieken, J. H., Lameris, A. L., and Drenth, J. P. (2008). Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. *Modern Pathol.* 21, 1293–1302. doi: 10.1038/modpathol.2008.113

Xu, Y., Shu, Z., Song, G., Liu, Y., Pang, P., Wen, X., et al. (2021). The role of preoperative computed tomography radiomics in distinguishing benign and malignant tumors of the parotid gland. *Front. Oncol.* 11:634452. doi: 10.3389/fonc.2021.634452

Zhang, G. F., Qiu, L., Yang, S. L., Wu, J. C., and Liu, T. J. (2020). Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. *Biosci. Rep.* 40:BiosciRep.20193353. doi: 10.1042/BiosciRep.20193353

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., et al. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* 10:1523. doi: 10.1038/s41467-019-09234-6

Zong, L., Zheng, S., Meng, Y., Tang, W., Li, D., Wang, Z., et al. (2021). Integrated transcriptomic analysis of the miRNA-mRNA interaction network in thin endometrium. *Front. Genet.* 12:589408. doi: 10.3389/fgene.2021.589408

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Lv, Xie, Pu, Wang, Yang, Pu, Ai, Liu, Chen and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.